Category: Press Releases

Genprex, Inc. Commences Initial Public Offering And Sets Price

AUSTIN, Texas, Oct. 13, 2017 /PRNewswire/ -- Genprex, Inc., ("Genprex") a clinical stage gene therapy company, today announced that its initial public offering of a minimum of 2.5 million shares and a maximum of 4.5 million shares of its common stock has priced at $5.00 per share.

Read More

Genprex to Present at Upcoming Investor and Industry Conferences

AUSTIN,Texas & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 1, 2018-- Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform

Read More

Genprex™ Taps Aldevron to Supply TUSC2 Plasmid DNA for Oncoprex Clinical Development Program

Newly manufactured plasmids will be applied in clinical trials evaluating Oncoprex™ in combination with targeted therapies and immunotherapies

Read More

Genprex CEO Updates Investors on Recent $10M Capital Raise and Progress of Oncoprex

AUSTIN, Texas & CAMBRIDGE, Mass.--Sept. 6, 2018-- Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform

Read More

Genprex Amends Options to License Additional Cancer Fighting Technologies from the University of Texas MD Anderson Cancer Center

AUSTIN, Texas & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 28, 2018-- Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today
Read More

Genprex to Present at Upcoming Investor Conferences

AUSTIN, Texas & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 21, 2018-- Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform

Read More

Genprex Provides Clinical and Corporate Update for Second Quarter 2018

AUSTIN, Texas--(BUSINESS WIRE)--Aug. 15, 2018-- Genprex, Inc. (NASDAQ:GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced a clinical and corporate update

Read More

Genprex Updates Agreement with University of Texas MD Anderson Cancer Center to Resume Patient Enrollment in Phase I/II Study Evaluating Oncoprex/Erlotinib Combination Therapy in Non-Small Cell Lung Cancer

AUSTIN,Texas & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 2, 2018-- Genprex, Inc. (NASDAQ:GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced that it has amended its agreement with The University of Texas

Read More

Genprex Enters Agreement with the University of Texas MD Anderson Cancer Center to Study Oncoprex in Combination with Immunotherapies

New study will evaluate synergistic effect of Oncoprex gene therapy on checkpoint inhibition.

Study may identify biomarkers that can predict the response to therapy across different cancers

Read More

Genprex To Present At The Singular Research Summer Solstice 2018 Conference

NEW YORK, July 18, 2018 /PRNewswire/ -- Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced that Rodney Varner, Chairman and Chief Executive Officer, will present

Read More

 
STAY IN THE KNOW WITH
EMAIL NEWS ALERTS
 
Don't miss out. Get our news delivered to your inbox.
 

 
close-link
 
Get Email News Alerts
 
close-link